Biolife Solutions, Inc. (NASDAQ:BLFS) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants Roderick de Greef - CFO, COO & Secretary Michael Rice - President, CEO & Director Conference Call Participants Jacob Johnson - Stephens Inc. Marc Wiesenberger - B. Riley FBR, Inc. Carl Byrnes - Northland Capital Markets Corey Deutsch - Analyst Operator Welcome to the BioLife Solutions Second Quarter 2020 Conference Call. My name is Rebecca, and I will be your operator for today's call. Opera ...

| --- | --- | --- | |----------------------------------------------------------------------------------------------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | We enable cell and gene therapy success by providing class-defining bioproduction solutions. | | | | | | | AUGUST 2020 NASDAQ : BLFS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to | --- | --- | |---------------------------------------------------------------------------------------|-------------------------------------------------- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) DELAWARE 94-3076866 (State or other jurisd ...

BioLife Solutions, Inc. (NASDAQ:BLFS) Q1 2020 Earnings Conference Call May 14, 2020 4:30 PM ET Company Participants Roderick de Greef - Chief Financial Officer Mike Rice - President & Chief Executive Officer Conference Call Participants Paul Knight - Janney Montgomery Suraj Kalia - Oppenheimer Jacob Johnson - Stephens Blair Cohn - H.C. Wainwright Thomas Flaten - Lake Street Capital Marc Wiesenberger - B. Riley FBR Christopher Hillary - Roubaix Capital Carl Byrnes - Northland Capital Operator Ladies and gent ...

NASDAQ : BLFS Q4 & FY2019 Earnings Call March 11, 2020 BioLife Solutions Q4 & FY2019 Earnings Call : March 11, 2020 1 Disclaimer NASDAQ: BLFS Cautions Regarding Forward Looking Statements Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements concerning the expected financial performance of the company fol ...

Company Overview - BioLife Solutions aims to be a leading supplier of bioproduction tools for cell and gene therapy in the regenerative medicine industry[5] - The company has a portfolio of products designed to improve the quality and de-risk cell and gene therapy manufacturing and delivery[7] - BioLife Solutions' products are used in nearly 400 customer applications[9] - The company is executing an M&A strategy to scale faster and solve more customer problems[11] Market and Products - The cell and gene therapy market is growing rapidly, rewarding innovators who can de-risk manufacturing, storage, and delivery[16] - BioLife Solutions offers biopreservation media, automated thawing products, cloud-connected shipping containers, and high-capacity storage freezers[14] - The company's biopreservation media, CryoStor and HypoThermosol, have demonstrated efficacy in over 425 articles, abstracts, and posters[30] - In 2019, SAVSU Technologies shipped 1,500 shipments using its cloud-connected shippers[56] Financial Performance - From January to September 2019, BioLife Solutions' revenue was $19 million, a 33% increase compared to $14.3 million in the same period of 2018[64] - The adjusted gross margin for January to September 2019 was 71%, a 200 bps increase from 69% in the same period of 2018[64] - Adjusted EBITDA for January to September 2019 was $4.3 million, a 7% increase compared to $4 million in the same period of 2018[64]

BioLife Solutions, Inc. (NASDAQ:BLFS) Q4 2019 Earnings Conference Call March 11, 2020 5:00 PM ET Company Participants Mike Rice – President and Chief Executive Officer Roderick de Greef – Chief Financial Officer Conference Call Participants Paul Knight – Janney Montgomery Suraj Kalia – Oppenheimer and Company Jacob Johnson – Stephens Thomas Flaten – Lake Street Capital Markets Edward Marks – H.C. Wainwright Marc Wiesenberger – B. Riley FBR Operator Ladies and gentlemen, thank you for standing-by and welcome ...

BioLife Solutions, Inc. (NASDAQ:BLFS) Q3 2019 Earnings Conference Call November 12, 2019 4:30 PM ET Company Participants Roderick de Greef - CFO Mike Rice - President and CEO Conference Call Participants Paul Knight - Janney Faizzan Ahmad - H.C. Wainwright William March - Spring City Partners Operator Good afternoon ladies and gentlemen and welcome to the Q3 2019 BioLife Solutions Incorporated Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a questi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 BioLife Solutions, Inc. (Exact name of registrant as specified in its charter) DELAWARE 94-3076866 (State or other j ...